Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales

Overview of attention for article published in PharmacoEconomics, April 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

policy: 2 policy sources

twitter: 2 X users

Citations

dimensions_citation: 69 Dimensions

Readers on

mendeley: 107 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 7 policy documents that reference this research output.

setmelanotide

Cited by Canadian Agency for Drugs and Technologies in Health on 20 Dec 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Larotrectinib for treating NTRK fusion-positive solid tumours : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 10 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Nusinersen for treating spinal muscular atrophy : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 04 Jun 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Nusinersen for treating spinal muscular atrophy : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 06 Aug 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

cysteamine bitartrate

Cited by Canadian Agency for Drugs and Technologies in Health on 02 Feb 2018

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Committee papers

Cited by National Institute for Health and Care Excellence on 08 Mar 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Assessment report

Cited by National Institute for Health and Care Excellence on 21 Dec 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.